Cargando…
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
BACKGROUND: Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoa...
Autores principales: | Apiquian, Rogelio, Córdoba, Rodrigo, Louzã, Mario |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035598/ https://www.ncbi.nlm.nih.gov/pubmed/21326651 http://dx.doi.org/10.2147/NDT.S15911 |
Ejemplares similares
-
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011) -
Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
por: Williams, Richard, et al.
Publicado: (2014) -
Cognitive impairment and its improvement after six months in adolescents with schizophrenia
por: Victoria, Gamaliel, et al.
Publicado: (2019) -
Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Singh, Dhiren, et al.
Publicado: (2009) -
Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
por: Catalán, Rosa, et al.
Publicado: (2011)